DISH Network Corp (DISH) Rushes In As Sprint Corporation (S) Backs Out Of T-Mobile US Inc (TMUS) Deal

“Just as one deal falls off the cliff, another potential suitor is there to maybe catch it,” reported Liz Claman of Fox Business in her after-hours web exclusive, Claman on Call.

“[...] We’re talking about DISH Network Corp (NASDAQ:DISH)’s chairman, Charlie Ergen, hinting today that he might be interested in buying wireless carrier T-Mobile US Inc (NYSE:TMUS). This comes on the heels of Sprint Corporation (NYSE:S) dropping out of the race for T-Mobile”, clarified Claman.

DISH Network Corp (NASDAQ:DISH)

DISH Network Corp (NASDAQ:DISH)’s CEO has been fond of Sprint Corporation (NYSE:S) itself and was entirely convinced of its potential to do much more to improve the wireless industry. In fact, he tried his hand at acquiring Sprint last year, but lost to the Japanese wireless carrier Softbank Corp. He seemed impressed by Sprint Corporation (NYSE:S)’s wireless spectrum and had plans to test a small scale wireless broadband project with it.

If there’s one thing that DISH Network Corp (NASDAQ:DISH) had in surplus, it was foresight. The American satellite service provider seems to have accumulated a vast spectrum over the years and is planning to put it to good use. With dwindling pay-TV subscribers, Ergen believed that the future is in wireless media to cater to the smartphone wielding millennial.

With the spectrum auctions to start on September 12th, DISH Network Corp (NASDAQ:DISH) can be expected to make a formal announcement anytime soon. Now that Sprint Corporation (NYSE:S) is no longer in the race, Dish is reported to have renewed interest in this matter. Analysts say that T-Mobile US Inc (NYSE:TMUS)’s expertise in the wireless technology combined with DISH Network Corp (NASDAQ:DISH)’s ’s spectrum availability is a sure shot winning combo.


Disclosure: none

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!